The reporting rate of pediatric anosmia and ageusia (age between 12-17 years) after COVID-19 vaccination was compared to the reporting rate after HPV and meningococcal vaccinations (vaccines given chiefly to the pediatric population) and influenza vaccinations in three periods: pre-COVID period (January 2019-August 2019), pre- COVID-19 vaccine period (April 2020-November 2020), and vaccine period (December 2020-July 2021). Six weeks after vaccination was defined as the risk period of probable association.

32, 0, 0, and 1 cases with anosmia and ageusia were reported after COVID-19, HPV, meningococcal and influenza vaccinations during the COVID-19 vaccination period respectively. The reporting rate of anosmia and ageusia after COVID-19 vaccination is 3.3 per million vaccinations which is significantly higher compared to cases after HPV, meningococcal and Influenza vaccinations during the COVID-19 vaccine period p<0.0001. Only one case of anosmia and ageusia was reported after meningococcal and Influenza vaccinations and no cases were reported after HPV vaccinations during the pandemic period. No cases were reported outside the pandemic and vaccination periods. Using self-controlled and case centered analyses, there is a significant difference in the reporting rate of anosmia and ageusia after COVID-19 vaccination between the risk period and control period (81.3% vs 3.1-12.5% p<0.0001).  However, the reporting rate is within the incidence range expected in the general population.